Surface Presentation of Hyaluronic Acid Modulates Nanoparticle-Cell Association
- PMID: 36282941
- PMCID: PMC9942780
- DOI: 10.1021/acs.bioconjchem.2c00412
Surface Presentation of Hyaluronic Acid Modulates Nanoparticle-Cell Association
Abstract
Nanoparticle (NP) drug carriers have revolutionized medicine and increased patient quality of life. Clinically approved formulations typically succeed because of reduced off-target toxicity of the cargo. However, increasing carrier accumulation at disease sites through precise targeting remains one of the biggest challenges in the field. Novel multivalent ligand presentations and self-assembled constructs can enhance cell association, but an inability to draw direct comparisons across formulations has hindered progress. Furthermore, how nanoparticle structure influences function often is unclear. In this report, we leverage the well-characterized hyaluronic acid (HA)-CD44 binding pair to investigate how the surface architecture of modified NPs impacts their association with ovarian cancer cells that overexpress CD44. We functionalized anionic liposomes with 5 kDa HA by either covalent conjugation via surface coupling or electrostatic self-assembly using the layer-by-layer (LbL) adsorption method. Comparing these two methods, we observed a consistent enhancement of NP-cell association with the self-assembly LbL technique, particularly with higher molecular weight (≥10 kDa) HA. To further optimize association, we increased the surface-available HA. We synthesized a bottlebrush glycopolymer composed of a polynorbornene backbone and pendant 5 kDa HA and layered this macromolecule onto NPs. Flow cytometry revealed that the LbL HA bottlebrush NP outperformed the LbL linear display of HA. Cellular visualization by deconvolution optical microscopy corroborated results from all three constructs. Using exogenous HA to block NP-CD44 interactions, we found the LbL HA bottlebrush NP had a 4-fold higher binding avidity than the best-performing LbL linear HA NP. We further observed that decreasing the density of HA bottlebrush side chains to 75% had minimal impact on LbL NP stability or cell association, though we did see a reduction in binding avidity with this side-chain-modified NP. Our studies indicate that LbL surfaces are highly effective for multivalent displays, and the mode in which they present a targeting ligand can be optimized for NP cell targeting.
Figures





Similar articles
-
GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.Int J Nanomedicine. 2016 Oct 7;11:5125-5147. doi: 10.2147/IJN.S113469. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27785019 Free PMC article.
-
Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles.ACS Nano. 2014 Aug 26;8(8):8374-82. doi: 10.1021/nn502861t. Epub 2014 Aug 11. ACS Nano. 2014. PMID: 25100313 Free PMC article.
-
Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.Pharm Res. 2014 Nov;31(11):2988-3005. doi: 10.1007/s11095-014-1393-4. Epub 2014 May 20. Pharm Res. 2014. PMID: 24842660
-
Hyaluronan-based Multifunctional Nano-carriers for Combination Cancer Therapy.Curr Top Med Chem. 2021;21(2):126-139. doi: 10.2174/1568026620666200922113846. Curr Top Med Chem. 2021. PMID: 32962617 Review.
-
Hyaluronan-modified nanoparticles for tumor-targeting.Expert Opin Drug Deliv. 2019 Sep;16(9):915-936. doi: 10.1080/17425247.2019.1645115. Epub 2019 Aug 6. Expert Opin Drug Deliv. 2019. PMID: 31387408 Review.
Cited by
-
Advancing engineering design strategies for targeted cancer nanomedicine.Nat Rev Cancer. 2025 Sep;25(9):657-683. doi: 10.1038/s41568-025-00847-2. Epub 2025 Aug 1. Nat Rev Cancer. 2025. PMID: 40751005 Review.
-
Hyaluronic Acid Nanoparticles with Parameters Required for In Vivo Applications: From Synthesis to Parametrization.Biomacromolecules. 2024 Aug 12;25(8):4934-4945. doi: 10.1021/acs.biomac.4c00370. Epub 2024 Jun 29. Biomacromolecules. 2024. PMID: 38943654 Free PMC article.
-
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.Int J Mol Sci. 2024 Jul 30;25(15):8304. doi: 10.3390/ijms25158304. Int J Mol Sci. 2024. PMID: 39125873 Free PMC article. Review.
-
Layer-by-Layer Polymer Functionalization Improves Nanoparticle Penetration and Glioblastoma Targeting in the Brain.ACS Nano. 2023 Dec 12;17(23):24154-24169. doi: 10.1021/acsnano.3c09273. Epub 2023 Nov 22. ACS Nano. 2023. PMID: 37992211 Free PMC article.
-
Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies.Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307809121. doi: 10.1073/pnas.2307809121. Epub 2024 Mar 4. Proc Natl Acad Sci U S A. 2024. PMID: 38437543 Free PMC article.
References
-
- Bangham AD; Standish MM; Watkins JC, Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Bio 1965, 13 (1), 238–IN27. - PubMed
-
- Allen TM; Cullis PR, Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliver. Rev 2013, 65 (1), 36–48. - PubMed
-
- Meyerhoff A, U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis. Clin. Infect. Dis 1999, 28 (1), 42–48. - PubMed
-
- Drug Approval Package: Arikayce Services, U. S. D. o. H. H., Ed. U.S. Food & Drug Administration: Silver Spring, MD, 2019.
-
- Barenholz Y, Doxil® — The first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160 (2), 117–134. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous